Literature DB >> 16597631

Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model.

Rajesh Pandey1, G K Khuller.   

Abstract

OBJECTIVES: To evaluate the potential of orally administered poly-lactide-co-glycolide (PLG, a synthetic polymer) nanoparticle encapsulated antituberculosis drugs (ATDs) (rifampicin + isoniazid + pyrazinamide + ethambutol) for cerebral drug delivery in a murine model.
METHODS: The formulation was prepared using the multiple emulsion technique and administered orally to mice for biodistribution, pharmacokinetic and chemotherapeutic studies.
RESULTS: A single oral dose of the formulation to mice could maintain sustained drug levels for 5-8 days in the plasma and for 9 days in the brain. There was a significant improvement in the pharmacokinetic parameters such as mean residence time and relative bioavailability as compared with free drugs. The pharmacodynamic parameters such as the ratio of area under the curve to minimum inhibitory concentration (AUC/MIC) and the time up to which MIC levels were maintained in plasma (T(MIC)) were also improved. In Mycobacterium tuberculosis H(37)Rv infected mice, five oral doses of the nanoparticle formulation administered every 10th day resulted in undetectable bacilli in the meninges, as assessed on the basis of cfu and histopathology.
CONCLUSIONS: Polymeric nanoparticles bear significant potential for ATD delivery to the brain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16597631     DOI: 10.1093/jac/dkl128

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

Review 1.  Engineered nanoparticulate drug delivery systems: the next frontier for oral administration?

Authors:  Roudayna Diab; Chiraz Jaafar-Maalej; Hatem Fessi; Philippe Maincent
Journal:  AAPS J       Date:  2012-07-06       Impact factor: 4.009

2.  Development and biological evaluation of a new nanotheranostic for tuberculosis.

Authors:  Edward Helal-Neto; Suyene Rocha Pinto; Filipe Leal Portilho; Marcellus Dias da Costa; Jonathas Xavier Pereira; Fiammetta Nigro; Eduardo Ricci-Junior; Andre Luis Peixoto Candéa; Maria das Graças Muller de Oliveira Henriques; Ralph Santos-Oliveira
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

Review 3.  Nanoparticle approaches against bacterial infections.

Authors:  Weiwei Gao; Soracha Thamphiwatana; Pavimol Angsantikul; Liangfang Zhang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-07-15

Review 4.  Nanoparticles for brain drug delivery.

Authors:  Massimo Masserini
Journal:  ISRN Biochem       Date:  2013-05-21

Review 5.  Nanotechnology-Based Approach in Tuberculosis Treatment.

Authors:  Mohammad Nasiruddin; Md Kausar Neyaz; Shilpi Das
Journal:  Tuberc Res Treat       Date:  2017-01-22

Review 6.  Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control.

Authors:  Afzal Hussain; Sima Singh; Sabya Sachi Das; Keshireddy Anjireddy; Subramanian Karpagam; Faiyaz Shakeel
Journal:  Curr Drug Deliv       Date:  2019       Impact factor: 2.565

7.  Formulation and optimization of temozolomide nanoparticles by 3 factor 2 level factorial design.

Authors:  Aviral Jain; Sanjay K Jain
Journal:  Biomatter       Date:  2013-04-01

Review 8.  Nanoparticles as potential new generation broad spectrum antimicrobial agents.

Authors:  Clarence S Yah; Geoffrey S Simate
Journal:  Daru       Date:  2015-09-02       Impact factor: 3.117

9.  Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages.

Authors:  Carmen A Molina-Torres; Alejandra Barba-Marines; Orestes Valles-Guerra; Jorge Ocampo-Candiani; Norma Cavazos-Rocha; Michael J Pucci; Jorge Castro-Garza; Lucio Vera-Cabrera
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-04-04       Impact factor: 3.944

10.  Temozolomide encapsulated and folic acid decorated chitosan nanoparticles for lung tumor targeting: improving therapeutic efficacy both in vitro and in vivo.

Authors:  Kaidi Li; Naixin Liang; Huaxia Yang; Hongsheng Liu; Shanqing Li
Journal:  Oncotarget       Date:  2017-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.